David Digomann

5PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 14, 2023
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer.

David Digomann, Max Heiduk, Charlotte Reiche

|May 16, 2023
VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer.

David Digomann, Johannes Strack, Max Heiduk

|May 04, 2023
TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.

Max Heiduk, Anna Klimova, Charlotte Reiche

|Jul 06, 2019
SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed.

David Digomann, Annett Linge, Anna Dubrovska

Pageof 1